Exchange: NASDAQ·Updated 11:51 PM EST

PDSB News

News
all
press releases
PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks
PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks
More News
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology (NASDAQ:PDSB) shares movedread more...
Benzinga
Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.
Stocktwits
Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.
Stocktwits
The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.
Stocktwits
PDS Biotech (NASDAQ:PDSB) is entering a potentially pivotal stretch with fresh capital, a high-profile new board member and a sharply narrowed clinical strategy centered on its PDS0301 immunocytokine.
24-7 Market News
Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing agreement.read more...
Benzinga
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares increased byread more...
Benzinga
PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.
Stocktwits

Advertisement|Remove ads.